Interferon-β and Anti-PD1/PD-L1 Checkpoint Blocakde Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells

被引：0
|
作者：
Kontny, U. [1 ]
Makowska, A. [1 ]
Braunschweig, T. [2 ]
Shen, L. [1 ]
Denecke, B. [3 ]
机构：
[1] RWTH Univ, Med Ctr, Pediat Hematol Oncol & Stem Cell Transplantat, Aachen, Germany
[2] RWTH Univ, Med Ctr, Pathol, Aachen, Germany
[3] RWTH Univ, Med Ctr, Interdisciplinary Ctr Clin Res, Aachen, Germany
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-664
引用
收藏
页码：S393 / S393
页数：1
相关论文
共 50 条
  • [21] The PD-L1 Expression predicts the Outcome of anti-PD-1/PD-L1-based Immune Checkpoint Therapy in Patients with metastatic Merkel Cell Carcinoma
    Schielke, L.
    Hadaschik, E.
    Lodde, G. C.
    Albrecht, L. J.
    Sucker, A.
    Tasdogan, A.
    Roesch, A.
    Zimmer, L.
    Livingstone, E.
    Becker, J. C.
    Schadendorf, D.
    Ugurel, S.
    Placke, J. M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 : 17 - 18
  • [22] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment
    Cheng, Jiaxing
    2020 INTERNATIONAL CONFERENCE ON ENERGY, ENVIRONMENT AND BIOENGINEERING (ICEEB 2020), 2020, 185
  • [24] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Sibaud, Vincent
    Meyer, Nicolas
    Lamant, Laurence
    Vigarios, Emmanuelle
    Mazieres, Julien
    Delord, Jean Pierre
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 254 - 263
  • [25] Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity
    Yang, Suah
    Shim, Man Kyu
    Song, Sukyung
    Cho, Hanhee
    Choi, Jiwoong
    Jeon, Seong Ik
    Kim, Woo Jun
    Um, Wooram
    Park, Jae Hyung
    Yoon, Hong Yeol
    Kim, Kwangmeyung
    BIOMATERIALS, 2022, 290
  • [26] Systemic analysis of innate responses to anti-PD1/PD-L1 treatment in a melanoma model
    Gassen, Rodrigo
    Welm, Alana
    Bonorino, Cristina
    CANCER RESEARCH, 2018, 78 (13)
  • [27] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Lipson, Evan J.
    Lilo, Mohammed T.
    Ogurtsova, Aleksandra
    Esandrio, Jessica
    Xu, Haiying
    Brothers, Patricia
    Schollenberger, Megan
    Sharfman, William H.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [28] High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment
    Sanchez-Magraner, Lissete
    Miles, James
    Baker, Claire L.
    Applebee, Christopher J.
    Lee, Dae-Jin
    Elsheikh, Somaia
    Lashin, Shaimaa
    Withers, Katriona
    Watts, Andrew G.
    Parry, Richard
    Edmead, Christine
    Lopez, Jose Ignacio
    Mehta, Raj
    Italiano, Antoine
    Ward, Stephen G.
    Parker, Peter J.
    Larijani, Banafshe
    CANCER RESEARCH, 2020, 80 (19) : 4244 - 4257
  • [29] Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy
    Le Burel, Sebastien
    Champiat, Stephane
    Routier, Emilie
    Aspeslagh, Sandrine
    Albiges, Laurence
    Szwebel, Tali-Anne
    Michot, Jean-Marie
    Chretien, Pascale
    Mariette, Xavier
    Voisin, Anne-Laure
    Lambotte, Olivier
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (03) : 468 - 470
  • [30] Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
    Messeha, Samia S.
    Zarmouh, Najla O.
    Soliman, Karam F. A.
    NUTRIENTS, 2021, 13 (05)
12345